2. Search Result
Search Result
Results for "

Anti-tumor effect

" in MedChemExpress (MCE) Product Catalog:

330

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dyes

2

Biochemical Assay Reagents

14

Peptides

27

Inhibitory Antibodies

74

Natural
Products

6

Isotope-Labeled Compounds

1

Click Chemistry

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103665
    STING agonist-3
    5+ Cited Publications

    		 STING Cancer
    STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
    STING agonist-3
  • HY-N0405
    Orientin
    5+ Cited Publications

    		 TNF Receptor Interleukin Related Neurological Disease Cancer
    Orientin is a neuroprotective agentinhibits which has anti-inflammation, anti-oxidative, anti-tumor, and cardio protection properties. Orientin inhibits the levels of IL-6, IL-1β and TNF-α. Orientin increases IL-10 level. Orientin exhibits neuroprotective effect by inhibits TLR4 and NF-kappa B signaling pathway. Orientin can used in study neuropathic pain .
    Orientin
  • HY-156856
    FL118-14-Propanol

    		ADC Payload Cancer
    FL118-14-Propanol is a FL118 derivative. FL118-14-Propanol synthesized ADC molecule has good anti-tumor effect in mice .
    FL118-14-Propanol
  • HY-N2515
    Ginsenoside Rk1
    5+ Cited Publications

    		 NF-κB PI3K JAK Apoptosis Inflammation/Immunology Cancer
    Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB . Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .
    Ginsenoside Rk1
  • HY-P990148
    Anti-Mouse VEGF-A Antibody (2G11-2A05)
    1 Publications Verification

    		 VEGFR Cancer
    Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a κ type antibody inhibitor, tragrting to mouse VEGF-A with high affinity. Anti-Mouse VEGF-A Antibody (2G11-2A05) shows good anti-tumor effect in gastric cancer xenograft models .
    Anti-Mouse VEGF-A Antibody (2G11-2A05)
  • HY-P9S0008
    Cetuximab (PBS)

    		Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect .
    Cetuximab (PBS)
  • HY-A0020
    Eldecalcitol
    4 Publications Verification

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    		 VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol
  • HY-156773
    STM3006
    2 Publications Verification

    		 Apoptosis METTL3 Cancer
    STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .
    STM3006
  • HY-N1346
    Robinin
    5 Publications Verification

    		 Toll-like Receptor (TLR) Apoptosis Inflammation/Immunology Cancer
    Robinin is a flavonoid that can be extracted from the leaves of purple cowpea, inhibiting TGF-β, TLR4/NF-κB and TLR2-PI3k-AKT signaling pathways. Robinin exerts anti-inflammatory and anti-tumor effects. The combination of Robinin and Methotrexate (HY-14519) reduces inflammation in experimental arthritis, Robinin can decrease the Doxorubicin (HY-15142A) induced cardiac toxicity effect .
    Robinin
  • HY-N0211
    Cyasterone
    2 Publications Verification

    		 EGFR Apoptosis Cancer
    Cyasterone, a natural EGFR inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced apoptosis and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors .
    Cyasterone
  • HY-145757
    Elevenostat
    1 Publications Verification

    JB3-22

    		 HDAC Apoptosis Caspase Cancer
    Elevenostat (JB3-22) is a selective HDAC11 inhibitor with an IC50 of 0.235 µM. Elevenostat can induce apoptosis of multiple myeloma cells and has anti-tumor effect. In addition, Elevenostat inhibits the maturation of mouse oocytes .
    Elevenostat
  • HY-107869
    Isoindigo

    		Fluorescent Dye Cancer
    Isoindigo acts as the acceptor unit in donor-acceptor (D-A) conjugated polymers and belongs to the indigo dye family. Isoindigo contains two lactam rings and exhibits strong electron-withdrawing properties. Isoindigo can be used in dyeing and pigment preparation. Isoindigo shows high mobility and excellent environmental stability in field-effect transistors (FETs). Isoindigo possesses the activity to inhibit tumor cell proliferation and has certain anti-tumor activity .
    Isoindigo
  • HY-P99489
    Budigalimab

    ABBV 181; PR 1648817

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
    Budigalimab
  • HY-B0910A
    Pyrithioxin dihydrochloride
    2 Publications Verification

    Pyritinol dihydrochloride; Pyridoxine disulfide dihydrochloride; Vitamin B6 disulfide dihydrochloride

    		 Drug Derivative Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Pyrithioxin (Pyritinol) dihydrochloride is the dihydrochloride salt of Pyrithioxin (HY-B0910). Pyrithioxin (Pyritinol) is an orally active neurodynamic compound. Pyrithioxin can promote the metabolism of glucose and amino acids, increase carotid blood flow and improve cerebral blood flow. Pyrithioxin exhibits anti-inflammation, anti-tumor and neuroprotective effect. Pyrithioxin can be used for the researches of cancer, inflammation, immunology, metabolic and neurological disease such as cerebral infarct, epilepsy, fibrosarcomas and rheumatoid polyarthritis .
    Pyrithioxin dihydrochloride
  • HY-175465
    SMI-10B13

    		Interleukin Related STAT Cancer
    SMI-10B13 is an Oncostatin M (OSM) inhibitor with a KD of 6.6 μM. SMI-10B13 inhibits OSM-mediated STAT3 phosphorylation in T47D and MCF-7 cell lines (IC50 = 136 and 164 nM, respectively). SMI-10B13 shows anti-tumor effect in human breast cancer mice models .
    SMI-10B13
  • HY-129467
    (Rac)-Idroxioleic acid

    2-Hydroxyoleic acid; 2-OHOA; LAM561

    		 Apoptosis Cancer
    (Rac)-Idroxioleic acid (2-Hydroxyoleic acid) is a synthetic oleic acid (OA) derivative that binds to the plasma membrane and alters lipid organization. (Rac)-Idroxioleic acid has anti-tumor effect .
    (Rac)-Idroxioleic acid
  • HY-153450
    JBI-589

    		Protein Arginine Deiminase Cancer
    JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .
    JBI-589
  • HY-156856S
    FL118-14-Propanol-d5

    		Isotope-Labeled Compounds ADC Payload Cancer
    FL118-14-Propanol-d5 is the deuterium labeled FL118-14-Propanol (HY-156856). FL118-14-Propanol is a FL118 derivative. FL118-14-Propanol synthesized ADC molecule has good anti-tumor effect in mice .
    FL118-14-Propanol-d5
  • HY-136780
    SEN177

    		Amyloid-β Apoptosis CD47 Huntingtin Neurological Disease Cancer
    SEN177 is an orally effect glutamine cyclase (QC) inhibitor. The Ki of SEN177 for human glutamine cyclase (hQC) is 20 nM, and the IC50 is 13 nM. SEN177 interferes with the interaction between CD47 and SIRRPα, and has anti-tumor activity. SEN177 reduces aggregation and apoptosis caused by HTT mutation in Huntington model, and can be used in the study of neurodegenerative diseases .
    SEN177
  • HY-119940
    MC180295
    1 Publications Verification

    (rel)-MC180295

    		 CDK Cancer
    MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC50 of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .
    MC180295
  • HY-16160
    Cysmethynil
    1 Publications Verification

    		 Autophagy ICMT Neurological Disease Cancer
    Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
    Cysmethynil
  • HY-175035
    HK-2-IN-1

    		Hexokinase Inflammation/Immunology Cancer
    HK-2-IN-1 is a Hexokinase 2 (HK-2) inhibitor. HK-2-IN-1 exhibits a non-activating effect on human recombinant HK-2 enzyme. HK-2-IN-1 has anti-tumor activity, affecting immune cells in the tumor microenvironment. HK-2-IN-1 has immunomodulatory effects and is potentially useful in the study of cancers such as colon cancer, liver cancer, and breast cancer .
    HK-2-IN-1
  • HY-113314
    AFMK

    		Endogenous Metabolite Cancer
    AFMK, antioxidant metabolite of Melatonin, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. AFMK is a poorer scavenger. The pKa of AFMK at physiological pH is 8.7. Antioxidant capacity . AFMK improves the anti-tumor effect of Gemcitabine in PANC-1 cells through the modulation of apoptotic pathway .
    AFMK
  • HY-159647B
    (1S,2S,3R)-PLX-4545

    		Molecular Glues IKZF Family Cancer
    (1S,2S,3R)-PLX-4545 is the (1S,2S,3R) enantiomer of PLX-4545 (HY-159647). PLX-4545 is an orally active and selective cereblon-based molecular glue degrader of IKZF2 (zinc finger transcription factor Helios). PLX-4545 can reprogram immunosuppressive regulatory T cells into pro-inflammatory effector T cells, thereby enhancing anti-tumor immune responses .
    (1S,2S,3R)-PLX-4545
  • HY-108986
    JFD00244

    		Sirtuin SARS-CoV Cancer
    JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2 .
    JFD00244
  • HY-156019
    FGFR1 inhibitor-10

    		FGFR Cancer
    FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .
    FGFR1 inhibitor-10
  • HY-103665A
    STING agonist-3 trihydrochloride
    5+ Cited Publications

    		 STING Cancer
    STING agonist-3 trihydrochloride, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pEC50 of 7.5 and 9.5, respectively. STING agonist-3 trihydrochloride has durable anti-tumor effect and tremendous potential to improve treatment of cancer .
    STING agonist-3 trihydrochloride
  • HY-117273
    AZ304

    		Raf Autophagy Cancer
    AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity .
    AZ304
  • HY-161853
    TX-2552

    		Phosphodiesterase (PDE) Others
    TX-2552 is an orally active tyrosine DNA phosphodiesterase 1 (TDP1) inhibitor with an IC50 value of 0.62 μM. TX-2552 can enhance the clastogenic activity of Topotecan (HY-13768) in mouse bone marrow cells, as well as the anti-tumor effect of Topotecan (HY-13768) in Krebs-2 ascites tumor mice .
    TX-2552
  • HY-163295
    BTK degrader-1

    		ADC Payload Btk Cancer
    BTK degrader-1 (compound 1) is a Bruton’s tyrosine kinase (BTK) bifunctional degrader that can be conjugated with CD79b. BTK degrader-1 (compound 1) has anti-tumor effect .
    BTK degrader-1
  • HY-15505
    RWJ-67657

    JNJ 3026582

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology Cancer
    RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .
    RWJ-67657
  • HY-162382
    KTC1101

    		PI3K Akt mTOR Cancer
    KTC1101 is an orally active pan-PI3K inhibitor. KTC1101 can inhibit the PI3K signaling pathway, reduce downstream AKT and mTOR phosphorylation, and reduces the expression of Ki67. The anti-tumor effect of KTC1101 has a dual mechanism of action: directly inhibiting tumor cell growth and dynamically enhancing immune response .
    KTC1101
  • HY-N8840
    Laricitrin

    		Others Cancer
    Laricitrin (compound 4) is an O-methylated flavonol, a type of flavonoid, that has anti-tumor effect .
    Laricitrin
  • HY-108520
    HX630

    		RAR/RXR Apoptosis Cancer
    HX630 is a potent retinoic acid X receptor (RXR) agonist, can induce apoptosis, has anti-tumor effect, and can be used in Cushing's disease research .
    HX630
  • HY-156569
    DGKα-IN-2

    		DGK Anaplastic lymphoma kinase (ALK) Inflammation/Immunology Cancer
    DGKα-IN-2 (example 48) is a DGKα inhibitor with the IC50 of 0.9 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
    DGKα-IN-2
  • HY-B0910
    Pyrithioxin
    2 Publications Verification

    Pyritinol; Pyridoxine disulfide; Vitamin B6 disulfide

    		 Drug Derivative Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Pyrithioxin (Pyritinol) is an orally active neurodynamic compound. Pyrithioxin can promote the metabolism of glucose and amino acids, increase carotid blood flow and improve cerebral blood flow. Pyrithioxin exhibits anti-inflammation, anti-tumor and neuroprotective effect. Pyrithioxin can be used for the researches of cancer, inflammation, immunology, metabolic and neurological disease such as cerebral infarct, epilepsy, fibrosarcomas and rheumatoid polyarthritis .
    Pyrithioxin
  • HY-P990257
    Anti-Mouse CSF1 Antibody (5A1)

    		c-Fms Cancer
    Anti-Mouse CSF1 Antibody (5A1) is a rat-derived anti-mouse CSF1 IgG1 κ type antibody inhibitor. Anti-Mouse CSF1 Antibody (5A1) can inhibit cells proliferation and macrophage-induced invasion. Anti-Mouse CSF1 Antibody (5A1) shows potent anti-tumor effect in various tumor models, such as neuroblastoma .
    Anti-Mouse CSF1 Antibody (5A1)
  • HY-172970
    HQY1428

    		CDK DNA/RNA Synthesis Apoptosis Cancer
    HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .
    HQY1428
  • HY-160160
    BAY-5516

    		PPAR Cancer
    BAY-5516 is a inverse-agonist o PPARG, with the IC50 value of 6.1±3.6 nM that has anti-tumor effect .
    BAY-5516
  • HY-N10781
    Isograndifoliol

    		Cholinesterase (ChE) Cardiovascular Disease Neurological Disease Cancer
    Isograndifoliol is a selective inhibitor of butyrylcholinesterase (BChE) with an IC50 value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC50 value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases .
    Isograndifoliol
  • HY-119340
    Mitoflaxone

    Flavoneacetic acid

    		 Reactive Oxygen Species (ROS) Cancer
    Mitoflaxone (flavoneacetic acid) is a synthetic flavonoid compound with vascular targeting properties. Mitoflaxone exerts anti-proliferative effects on endothelial cells through a superoxide-dependent mechanism, this effect leads to changes in the permeability of tumor blood vessels, thereby exerting anti-tumor effects [1] [2] .
    Mitoflaxone
  • HY-10438
    BMS-577098

    		IGF-1R Cancer
    BMS-577098 is an orally active and ATP-competitive insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 0.016 μM. BMS-577098 shows anti-tumor effect .
    BMS-577098
  • HY-P10652
    hsBCL9CT-24

    		Wnt β-catenin Cancer
    hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research .
    hsBCL9CT-24
  • HY-153396
    Acid Ceramidase-IN-2

    		Ceramidase Cancer
    Acid Ceramidase-IN-2 (compound 1) is an acid ceramidase inhibitor with potentially antiproliferative and cytostatic activities. Moreover, human acid ceramidase is overexpressed in prostate cancer cells, indicating potential anti-tumor effect of Acid Ceramidase-IN-2. And Acid Ceramidase-IN-2 hydrolysis can be inhibited by 3 a-ketoamides GT85, GT98 and GT99 inhibits in vitro .
    Acid Ceramidase-IN-2
  • HY-143265
    Topoisomerase I inhibitor 2

    		Topoisomerase Apoptosis Caspase Cancer
    Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect .
    Topoisomerase I inhibitor 2
  • HY-106603
    Sulofenur

    Diarylsulfonylurea; LY186641

    		 Calcium Channel Cancer
    Sulofenur (LY186641) is an orally active anti-tumor agent. Sulofenur induces gene expression through calcium ion-dependent pathways and some protein kinase-independent pathways, and its effect is particularly enhanced in H-ras mutant cells. Sulofenur exhibits significant activity in mouse solid tumor models and human tumor xenograft models .
    Sulofenur
  • HY-A0020R
    Eldecalcitol (Standard)

    ED-71 (Standard); 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 (Standard)

    		 Reference Standards VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol (Standard)
  • HY-161886
    SMARCA2-IN-7

    		SWI/SNF Complex Epigenetic Reader Domain Cancer
    SMARCA2-IN-7 (compound 12), a dual inhibitor of BRM and BRG1 (IC50 < 0.005 for both), has an anti-tumor proliferation effect that inhibits BRG1-deleted SKMEL5 tumor proliferation with a cell proliferation activity AAC50 of 13 nM in SKMEL5. The cell proliferation activity AAC50 of KRT880 in H1299 cells was 42 nM .
    SMARCA2-IN-7
  • HY-174989
    ATM-IN-2

    		ATM/ATR Apoptosis Cancer
    ATM-IN-2 is a selective and orally active ATM inhibitor with an IC50 of 4 nM. ATM-IN-2 exhibits excellent kinase selectivity (>700-fold over PIKK family members). ATM-IN-2 exerts its anti-tumor effect by inhibiting ATM phosphorylation and the downstream signaling pathways (p53, H2AX), and promotes cell apoptosis. ATM-IN-2 can be used for the study of chemosensitizer candidate such as colon cancer .
    ATM-IN-2
  • HY-179288
    TPST2-IN-1

    		Transmembrane Glycoprotein STAT Cancer
    TPST2-IN-1 is a potent and selective TPST2 inhibitor with an IC50 of 946 nM and a Ka of 19.4 μM. TPST2-IN-1 increases the phosphorylation of Stat1 and upregulates the IFNγ-responsive gene CXCL10 by inhibiting TPST2 activity.TPST2-IN-1 exhibits anti-tumor activity and enhances T cell-mediated antitumor immunity characterized by increased infiltration of effector CD8 + T cells. TPST2-IN-1 can be used for the research of cancer, such as colon cancer .
    TPST2-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: